Streetbeat News

Analyst Ratings

ZIM

Barclays analyst Alexia Dogani maintains an Underweight rating on ZIM Integrated Shipping (NYSE:ZIM) and lowers the price target from $10.6 to $9.5.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:13 am

RVTY

Barclays analyst Luke Sergott maintains an Equal-Weight rating on Revvity (NYSE:RVTY) and lowers the price target from $130 to $120.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:11 am

TRMB

Raymond James analyst Brian Gesuale has upgraded Trimble (NASDAQ:TRMB) from Market Perform to Outperform and announced a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:10 am

PACB

Barclays analyst Luke Sergott maintains an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) and lowers the price target from $14 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:08 am

IQV

Barclays analyst Luke Sergott maintains an Overweight rating on IQVIA Holdings (IQV) but lowers the price target from $250 to $245.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:07 am

ILMN

Barclays analyst Luke Sergott maintains an Underweight rating on Illumina (NASDAQ:ILMN) and has lowered the price target from $150 to $100.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:05 am

CTLT

Barclays analyst Luke Sergott has maintained an Equal-Weight rating on Catalent (NYSE:CTLT) and lowered the price target from $55 to $50.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:02 am

AVTR

Barclays analyst Luke Sergott maintains an Overweight rating on Avantor (NYSE:AVTR) and raises the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:00 am

BMBL

BROG

EDIT

FOLD

NKE

NVGS

OPK

STEM

Several stocks including Brooge Energy Limited, OPKO Health, NIKE, Editas Medicine, Amicus Therapeutics, Navigator Holdings, Bumble, and Stem are recording gains in Friday's pre-market trading session. Notable developments include OPKO's ModeX Therapeutics being awarded a BARDA Contract, NIKE posting upbeat quarterly earnings, and Editas Medicine being upgraded by Stifel from Hold to Buy.

Portfolio Pulse from Lisa Levin

September 29, 2023 | 9:59 am

A

Barclays analyst Jack Meehan maintains an Underweight rating on Agilent Technologies (NYSE:A) and has lowered the price target from $110 to $105.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 9:56 am